Skip to main content

Table 2 TTF rate point estimates and 95% confidence intervals for the 30 mg, 40 mg and 50 mg vinorelbine groups (TTF refers to time from treatment initiation to discontinuation for any reason)

From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

  Patients (%) on treatment  
Vinorelbine dose arm (mg) At 4 months   At 6 months  
   p value   p value
30 25.9% (11.1-46.2%) 0.56 22.2% (8.6-57.7%) 0.39
40 33.3% (15.6-55.6%) 8.3% (1.0-27.0%)
50 18.2% (5.2-20.3%) 13.6% (2.9-34.9%)